Achondroplasia is the most common form of short-limbed dwarfism, affecting approximately 1 in 15,000-40,000 live births. It is caused by gain-of-function mutations in FGFR3, with over 95% of cases resulting from the G380R (c.1138G>A) mutation. The constitutively active FGFR3 receptor inhibits chondrocyte proliferation and differentiation in growth plate cartilage, leading to impaired endochondral ossification and disproportionate short stature with rhizomelic limb shortening, macrocephaly, frontal bossing, and characteristic trident hand configuration. Complications include foramen magnum stenosis with risk of cervicomedullary compression in infancy, progressive spinal stenosis, obstructive sleep apnea, recurrent otitis media, and obesity. Vosoritide, a C-type natriuretic peptide analog that antagonizes FGFR3 signaling, was approved by the FDA in 2021 as the first disease-modifying therapy.
Ask a research question about Achondroplasia. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Achondroplasia
creation_date: '2026-02-02T00:16:36Z'
updated_date: '2026-04-28T00:00:00Z'
category: Mendelian
description: >
Achondroplasia is the most common form of short-limbed dwarfism, affecting approximately
1 in 15,000-40,000 live births. It is caused by gain-of-function mutations in FGFR3,
with over 95% of cases resulting from the G380R (c.1138G>A) mutation. The constitutively
active FGFR3 receptor inhibits chondrocyte proliferation and differentiation in
growth plate cartilage, leading to impaired endochondral ossification and disproportionate
short stature with rhizomelic limb shortening, macrocephaly, frontal bossing, and
characteristic trident hand configuration. Complications include foramen magnum stenosis
with risk of cervicomedullary compression in infancy, progressive spinal stenosis,
obstructive sleep apnea, recurrent otitis media, and obesity. Vosoritide, a C-type
natriuretic peptide analog that antagonizes FGFR3 signaling, was approved by the FDA
in 2021 as the first disease-modifying therapy.
disease_term:
preferred_term: achondroplasia
term:
id: MONDO:0007037
label: achondroplasia
parents:
- FGFR3-related skeletal dysplasia
- Rhizomelic limb shortening syndrome
inheritance:
- name: Autosomal dominant
inheritance_term:
preferred_term: Autosomal dominant inheritance
term:
id: HP:0000006
label: Autosomal dominant inheritance
penetrance: COMPLETE
de_novo_rate: ">90"
parent_of_origin_effect: Increased paternal age; de novo mutations of paternal origin
description: >
Achondroplasia follows autosomal dominant inheritance with complete penetrance.
Approximately 80% of cases arise from de novo mutations, typically in the paternal
germline with advanced paternal age as a risk factor. Homozygous achondroplasia
is lethal.
evidence:
- reference: PMID:8078586
reference_title: "Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Affected individuals are fertile and achondroplasia is transmitted as a fully penetrant autosomal dominant trait, accounting for rare familial forms of the disease (10%)."
explanation: Establishes autosomal dominant inheritance with full penetrance for achondroplasia.
- reference: PMID:8078586
reference_title: "Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "More than 90% of cases are sporadic and there is an increased paternal age at the time of conception of affected individuals,"
explanation: Indicates that most cases are de novo and associated with increased paternal age, supporting a paternal origin effect.
- reference: ORPHA:15
supports: SUPPORT
snippet: "Autosomal dominant"
explanation: Orphanet classifies achondroplasia inheritance as autosomal dominant.
prevalence:
- population: Global live births
percentage: 4.6 per 100,000
notes: >-
A systematic review and meta-analysis estimated worldwide birth prevalence
at 4.6 per 100,000 live births, with a somewhat lower population-based
European estimate of 3.72 per 100,000 births.
evidence:
- reference: PMID:32803853
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Based on the meta-analysis, the worldwide birth prevalence of achondroplasia was estimated to be 4.6 per 100,000."
explanation: This meta-analysis provides the strongest aggregate global birth-prevalence estimate for achondroplasia.
- reference: PMID:31294928
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The study population consisted of 434 achondroplasia cases with a prevalence of 3.72 per 100,000 births (95%CIs: 3.14-4.39)."
explanation: A large EUROCAT population-based study corroborates the rarity of achondroplasia and provides a robust European prevalence estimate.
- reference: ORPHA:15
supports: SUPPORT
snippet: "1-9 / 100 000 | Worldwide | Prevalence at birth | PMID:32803853"
explanation: Orphanet epidemiology data confirm worldwide birth prevalence in the 1-9 per 100,000 range, consistent with published estimates.
mechanistic_hypotheses:
- hypothesis_group_id: canonical_fgfr3_gain_of_function_chondrocyte_model
hypothesis_label: Canonical FGFR3 Gain-of-Function Chondrocyte Model
status: CANONICAL
description: >-
A recurrent heterozygous activating mutation in FGFR3 (most commonly G380R) produces a constitutively active fibroblast growth factor receptor 3 that hyperactivates STAT1, MAPK/ERK, and p38 MAPK signaling in growth-plate chondrocytes. The resulting inhibition of chondrocyte proliferation and accelerated terminal differentiation impair endochondral ossification, producing rhizomelic short stature, macrocephaly with frontal bossing, midface hypoplasia, foramen magnum stenosis, and characteristic trident hand. C-type natriuretic peptide analogues (vosoritide) that antagonize downstream MAPK signaling directly validate the FGFR3-signaling axis as the pathogenic driver.
notes: >-
Retained as CANONICAL. The 2026 openscientist
hypothesis-search report
(kb/hypotheses/Achondroplasia/canonical_fgfr3_gain_of_function_chondrocyte_model)
found the model among the most thoroughly validated in human genetics.
Heterozygous FGFR3 G380R produces hyperactive STAT1/MAPK/ERK/p38
signaling in growth-plate chondrocytes, impairing endochondral
ossification. Vosoritide (CNP analog antagonizing MAPK) provides
direct interventional validation. Three qualifications: (1) the
mechanism is best described as **impaired receptor downregulation
and increased phosphorylation of unliganded dimers**, not strict
constitutive activation; (2) FGFR3 mutations vary in severity by
activation strength (G380R achondroplasia vs K650 thanatophoric
dysplasia); (3) foramen-magnum stenosis, cervicomedullary compression
and sleep apnea reflect cranial-base-specific endochondral defects
not fully addressed by long-bone-targeted FGFR3 antagonists.
evidence:
- reference: PMID:7913883
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "DNA studies revealed point mutations in the FGFR3 gene in ACH"
explanation: >
Canonical mechanism review used as the seed reference for the
hypothesis-search deep-research run.
pathophysiology:
- name: FGFR3 gain-of-function signaling
conforms_to: "fgfr_gain_of_function_skeletal_dysplasia#Constitutive FGFR Activation"
description: >
The FGFR3 G380R mutation causes constitutive activation of the receptor, leading
to enhanced downstream signaling through STAT1, MAPK/ERK, and p38 MAPK pathways.
This results in premature cell cycle arrest of growth plate chondrocytes, reduced
chondrocyte proliferation and hypertrophy, and impaired endochondral bone formation.
The receptor normally serves as a negative regulator of bone growth; its overactivation
leads to the shortened long bones characteristic of achondroplasia.
pdb_structures:
- pdb_id: 4BSK
description: FGFR3 kinase domain crystal structure showing the constitutively active conformation caused by achondroplasia-associated pathogenic mutations
resolution_angstrom: 2.3
method: X-ray
target_protein: FGFR3 kinase domain
publication: PMID:24297434
gene:
preferred_term: FGFR3
description: Fibroblast growth factor receptor 3, a transmembrane tyrosine kinase receptor that negatively regulates endochondral bone growth.
modifier: INCREASED
term:
id: hgnc:3690
label: FGFR3
evidence:
- reference: PMID:7913883
reference_title: "Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "DNA studies revealed point mutations in the FGFR3 gene in ACH heterozygotes and homozygotes. The mutation on 15 of the 16 ACH-affected chromosomes was the same, a G-->A transition, at nucleotide 1138 of the cDNA."
explanation: This landmark 1994 Cell paper by Shiang et al. identified FGFR3 mutations as the cause of achondroplasia, establishing the molecular basis of the disease.
- reference: PMID:7847369
reference_title: "Achondroplasia is defined by recurrent G380R mutations of FGFR3."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "All but one, an atypical case, were found to have a glycine-to-arginine substitution at codon 380. Of these, 150 had a G-to-A transition at nt 1138, and 3 had a G-to-C transversion at this same position."
explanation: This study of 154 unrelated achondroplasia patients confirmed the G380R mutation is essentially universal, with over 97% having the same recurrent mutation.
- reference: ORPHA:15
supports: SUPPORT
snippet: "FGFR3 | fibroblast growth factor receptor 3 | hgnc:3690 | Disease-causing germline mutation(s) (gain of function) in"
explanation: Orphanet gene-disease association confirms FGFR3 gain-of-function as the causal mechanism.
cell_types:
- preferred_term: Growth plate chondrocyte
term:
id: CL:1000217
label: growth plate cartilage chondrocyte
- preferred_term: Hypertrophic chondrocyte
term:
id: CL:0000743
label: hypertrophic chondrocyte
biological_processes:
- preferred_term: FGFR signaling pathway
term:
id: GO:0008543
label: fibroblast growth factor receptor signaling pathway
- preferred_term: Endochondral ossification
term:
id: GO:0001958
label: endochondral ossification
- preferred_term: Chondrocyte differentiation
term:
id: GO:0002062
label: chondrocyte differentiation
downstream:
- target: MAPK-mediated inhibition of chondrocyte differentiation
- target: Impaired growth plate cartilage development
- name: MAPK-mediated inhibition of chondrocyte differentiation
conforms_to: "fgfr_gain_of_function_skeletal_dysplasia#Growth-Plate Chondrocyte Dysregulation"
description: >
The MAPK/ERK cascade is a principal effector of FGFR3-driven growth inhibition.
Constitutive activation of MEK1 in chondrocytes causes achondroplasia-like dwarfism
with incomplete hypertrophy and delayed endochondral ossification, while chondrocyte
proliferation remains unaffected. The MAPK pathway inhibits hypertrophic differentiation,
and STAT1 mediates inhibition of chondrocyte proliferation as a parallel pathway.
Upregulation of FGFR3, Stat1, Stat5, and p21Cip1 in the prehypertrophic-hypertrophic
zone correlates with disease severity and impaired chondrocyte differentiation.
cell_types:
- preferred_term: Growth plate chondrocyte
term:
id: CL:1000217
label: growth plate cartilage chondrocyte
- preferred_term: Prehypertrophic chondrocyte
term:
id: CL:0020022
label: prehypertrophic chondrocyte
biological_processes:
- preferred_term: MAPK cascade
term:
id: GO:0000165
label: MAPK cascade
modifier: INCREASED
- preferred_term: Chondrocyte differentiation
term:
id: GO:0002062
label: chondrocyte differentiation
modifier: DECREASED
evidence:
- reference: PMID:14871928
reference_title: "Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "These observations indicate that the MAPK pathway inhibits hypertrophic differentiation of chondrocytes and negatively regulates bone growth without inhibiting chondrocyte proliferation."
explanation: Demonstrates that MAPK pathway specifically inhibits chondrocyte differentiation rather than proliferation, with constitutive MEK1 activation recapitulating the achondroplasia phenotype in mice.
- reference: PMID:14871928
reference_title: "Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "These observations suggest a model in which Fgfr3 signaling inhibits bone growth by inhibiting chondrocyte differentiation through the MAPK pathway and by inhibiting chondrocyte proliferation through Stat1."
explanation: Establishes the dual-pathway model where MAPK inhibits differentiation and STAT1 inhibits proliferation downstream of FGFR3.
- reference: PMID:14751560
reference_title: "Overexpression of FGFR3, Stat1, Stat5 and p21Cip1 correlates with phenotypic severity and defective chondrocyte differentiation in FGFR3-related chondrodysplasias."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "Our results indicate that FGFR3 mutations in the prenatal period upregulate FGFR3 and Stat-p21Cip1 expression, thus inducing premature exit of proliferative cells from the cell cycle and their differentiation into prehypertrophic chondrocytes."
explanation: Human fetal tissue analysis confirms that FGFR3 mutations upregulate STAT/p21 signaling in growth plate chondrocytes, causing premature cell cycle exit and defective differentiation.
- name: Impaired growth plate cartilage development
conforms_to: "fgfr_gain_of_function_skeletal_dysplasia#Impaired Endochondral Ossification and Chondrodysplasia"
description: >
In the growth plate, FGFR3 overactivation disrupts the normal columnar organization
of chondrocytes and reduces the height of the proliferative and hypertrophic zones.
This results in shortened and disorganized growth plates with reduced longitudinal
bone growth, particularly affecting the long bones of the limbs (rhizomelic pattern)
and the skull base (leading to foramen magnum stenosis).
cell_types:
- preferred_term: Columnar chondrocyte
term:
id: CL:0000744
label: columnar chondrocyte
biological_processes:
- preferred_term: Growth plate chondrocyte differentiation
term:
id: GO:0003418
label: growth plate cartilage chondrocyte differentiation
- preferred_term: Growth plate cartilage development
term:
id: GO:0003417
label: growth plate cartilage development
evidence:
- reference: PMID:14751560
reference_title: "Overexpression of FGFR3, Stat1, Stat5 and p21Cip1 correlates with phenotypic severity and defective chondrocyte differentiation in FGFR3-related chondrodysplasias."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "Immunohistochemical analysis of fetal growth plates showed a phenotype-related reduction of the collagen type X-positive hypertrophic zone."
explanation: Direct histological evidence from human fetal growth plates showing reduced hypertrophic zone in achondroplasia, confirming impaired growth plate cartilage development.
downstream:
- target: Cranial base synchondrosis closure
- name: Cranial base synchondrosis closure
description: >
FGFR3-MAPK activation accelerates closure of cranial base synchondroses and
fusion of ossification centers, leading to premature cranial base fusion and
narrowing of the foramen magnum. This mechanism underlies the foramen magnum
stenosis that poses a risk of cervicomedullary compression and sudden death in infancy.
cell_types:
- preferred_term: Growth plate chondrocyte
term:
id: CL:1000217
label: growth plate cartilage chondrocyte
biological_processes:
- preferred_term: MAPK cascade
term:
id: GO:0000165
label: MAPK cascade
modifier: INCREASED
- preferred_term: Endochondral ossification
term:
id: GO:0001958
label: endochondral ossification
evidence:
- reference: PMID:18923003
reference_title: "FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "We observed premature synchondrosis closure in the spine and cranial base in human cases of homozygous achondroplasia and thanatophoric dysplasia as well as in mouse models of achondroplasia."
explanation: Direct evidence that FGFR3 activation causes premature synchondrosis closure in cranial base, demonstrated in both human skeletal dysplasia cases and mouse models.
- reference: PMID:18923003
reference_title: "FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "Chondrocyte-specific activation of Fgfr3 in mice induced premature synchondrosis closure and enhanced osteoblast differentiation around synchondroses."
explanation: Shows that FGFR3 activation specifically in chondrocytes is sufficient to drive premature synchondrosis closure through a MAPK-dependent mechanism involving enhanced bone formation.
- reference: PMID:14871928
reference_title: "Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "Immunohistochemical analysis of the cranial base in transgenic embryos showed reduced staining for collagen type X and persistent expression of Sox9 in chondrocytes."
explanation: Shows molecular disruption of cranial base chondrocyte maturation upon MAPK activation, consistent with premature closure mechanism.
- name: CNP-NPR2 counter-regulatory pathway
conforms_to: "fgfr_gain_of_function_skeletal_dysplasia#CNP-NPR2 Counter-Regulation and FGFR-Pathway Antagonist Therapy"
description: >
C-type natriuretic peptide (CNP) signaling through NPR-B (NPR2) physiologically
antagonizes FGFR3-MAPK activity in growth plate chondrocytes. CNP inhibits the
MAPK pathway downstream of FGFR3, correcting decreased extracellular matrix synthesis
but not affecting the STAT1-mediated proliferation defect. This counter-regulatory
pathway provides the mechanistic rationale for CNP analog therapy (vosoritide).
cell_types:
- preferred_term: Growth plate chondrocyte
term:
id: CL:1000217
label: growth plate cartilage chondrocyte
biological_processes:
- preferred_term: Receptor guanylyl cyclase signaling pathway
term:
id: GO:0007168
label: receptor guanylyl cyclase signaling pathway
- preferred_term: MAPK cascade
term:
id: GO:0000165
label: MAPK cascade
modifier: DECREASED
evidence:
- reference: PMID:14702637
reference_title: "Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "CNP prevented the shortening of achondroplastic bones by correcting the decreased extracellular matrix synthesis in the growth plate through inhibition of the MAPK pathway of FGF signaling."
explanation: Demonstrates the mechanism by which CNP counteracts FGFR3 overactivation specifically through MAPK pathway inhibition, establishing the basis for vosoritide therapy.
- reference: PMID:14702637
reference_title: "Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "CNP had no effect on the STAT-1 pathway of FGF signaling that mediates the decreased proliferation and the delayed differentiation of achondroplastic chondrocytes."
explanation: Shows that CNP selectively inhibits MAPK but not STAT1, explaining why CNP therapy partially but not completely rescues the achondroplasia phenotype.
phenotypes:
- name: Disproportionate short stature
description: >
Disproportionate short-limb short stature is a defining skeletal manifestation
of achondroplasia.
phenotype_term:
preferred_term: Disproportionate short-limb short stature
term:
id: HP:0008873
label: Disproportionate short-limb short stature
evidence:
- reference: PMID:32803853
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Achondroplasia is a genetic disorder that results in disproportionate short stature."
explanation: Supports disproportionate short stature as a core phenotype of achondroplasia.
- name: Rhizomelia
frequency: OCCASIONAL
description: >
Shortening is most pronounced in the proximal long bones. Orphanet codes
the strict HPO term HP:0008905 (Rhizomelia) as Occasional; the broader
rhizomelic shortening pattern is universally present but captured under
Disproportionate short stature and Limb undergrowth.
phenotype_term:
preferred_term: Rhizomelia
term:
id: HP:0008905
label: Rhizomelia
evidence:
- reference: PMID:29972438
reference_title: "Natural history of 39 patients with Achondroplasia."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The most prevalent radiographic findings were rhizomelic shortening of the long bones and narrowing of the interpediculate distance of the caudal spine."
explanation: Supports rhizomelic long-bone shortening as a characteristic skeletal manifestation.
- reference: ORPHA:15
supports: SUPPORT
snippet: "HP:0008905 | Rhizomelia | Occasional (29-5%)"
explanation: Orphanet classifies rhizomelia as occasional in achondroplasia.
- name: Macrocephaly
frequency: FREQUENT
description: >
Macrocephaly is part of the characteristic cranial phenotype.
phenotype_term:
preferred_term: Macrocephaly
term:
id: HP:0000256
label: Macrocephaly
evidence:
- reference: PMID:29972438
reference_title: "Natural history of 39 patients with Achondroplasia."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The most prevalent clinical findings were short stature, high forehead, trident hands, genu varum and macrocephaly."
explanation: Clinical cohort data identify macrocephaly as one of the most prevalent physical findings.
- reference: ORPHA:15
supports: SUPPORT
snippet: "HP:0000256 | Macrocephaly | Frequent (79-30%)"
explanation: Orphanet classifies macrocephaly as frequent in achondroplasia.
- name: Prominent forehead
description: >
Prominent forehead is a characteristic craniofacial feature.
phenotype_term:
preferred_term: Prominent forehead
term:
id: HP:0011220
label: Prominent forehead
evidence:
- reference: PMID:37072824
reference_title: "Craniofacial growth and function in achondroplasia: a multimodal 3D study on 15 patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Craniofacial phenotype was characterized by maxillo-zygomatic retrusion, deep nasal root, and prominent forehead."
explanation: Multimodal craniofacial study directly documents prominent forehead in pediatric achondroplasia.
- name: Midface retrusion
description: >
Midface retrusion contributes to the characteristic craniofacial appearance.
phenotype_term:
preferred_term: Midface retrusion
term:
id: HP:0011800
label: Midface retrusion
evidence:
- reference: PMID:37072824
reference_title: "Craniofacial growth and function in achondroplasia: a multimodal 3D study on 15 patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Craniofacial phenotype was characterized by maxillo-zygomatic retrusion, deep nasal root, and prominent forehead."
explanation: Maxillo-zygomatic retrusion directly supports midface retrusion as a core craniofacial phenotype.
- name: Trident hand
frequency: FREQUENT
description: >
Trident hand is a characteristic hand configuration in achondroplasia.
phenotype_term:
preferred_term: Trident hand
term:
id: HP:0004060
label: Trident hand
evidence:
- reference: PMID:29972438
reference_title: "Natural history of 39 patients with Achondroplasia."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The most prevalent clinical findings were short stature, high forehead, trident hands, genu varum and macrocephaly."
explanation: Clinical cohort data identify trident hands as one of the most prevalent physical findings.
- reference: ORPHA:15
supports: SUPPORT
snippet: "HP:0004060 | Trident hand | Frequent (79-30%)"
explanation: Orphanet classifies trident hand as frequent in achondroplasia.
- name: Genu varum
description: >
Genu varum is a common lower-limb deformity and is typically recognized during childhood.
phenotype_term:
preferred_term: Genu varum
term:
id: HP:0002970
label: Genu varum
evidence:
- reference: PMID:29972438
reference_title: "Natural history of 39 patients with Achondroplasia."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The most prevalent clinical findings were short stature, high forehead, trident hands, genu varum and macrocephaly."
explanation: Clinical cohort data identify genu varum as one of the most prevalent physical findings.
- name: Thoracolumbar kyphosis
frequency: VERY_FREQUENT
description: >
Thoracolumbar kyphosis is common in young children and often improves over time.
phenotype_term:
preferred_term: Thoracolumbar kyphosis
term:
id: HP:0005619
label: Thoracolumbar kyphosis
evidence:
- reference: PMID:37493935
reference_title: "Walking status and spinopelvic parameters in young children with achondroplasia: 10-year follow-up."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Thoracolumbar kyphosis (TLK) is common in children with achondroplasia and resolves in 90% by 10 years of age."
explanation: Supports both childhood onset and the usual tendency toward spontaneous improvement by age 10.
- reference: PMID:27927547
reference_title: "Prevalence of Scoliosis and Thoracolumbar Kyphosis in Patients With Achondroplasia."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Thoracolumbar kyphosis was observed in 79%, with 52% exhibiting moderate to severe curvature."
explanation: Large orthopedic cohort documents thoracolumbar kyphosis as a common spinal phenotype.
- reference: ORPHA:15
supports: SUPPORT
snippet: "HP:0005619 | Thoracolumbar kyphosis | Very frequent (99-80%)"
explanation: Orphanet classifies thoracolumbar kyphosis as very frequent in achondroplasia.
- name: Scoliosis
description: >
Scoliosis is a common spinal deformity in achondroplasia.
phenotype_term:
preferred_term: Scoliosis
term:
id: HP:0002650
label: Scoliosis
evidence:
- reference: PMID:27927547
reference_title: "Prevalence of Scoliosis and Thoracolumbar Kyphosis in Patients With Achondroplasia."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Scoliosis was observed in 60%."
explanation: Large orthopedic cohort documents scoliosis in 60% of patients with achondroplasia.
- name: Foramen magnum stenosis
description: >
Foramen magnum stenosis is a major infant complication that can cause cervical cord compression.
phenotype_term:
preferred_term: Small foramen magnum
term:
id: HP:0002677
label: Small foramen magnum
evidence:
- reference: PMID:32883660
reference_title: "Achondroplasia Foramen Magnum Score: screening infants for stenosis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Of 36 infants (M:F, 18:18), 2 (5.6%) did not have FMS (AFMS0); 13 (36.1%) had FMS with preservation of the cerebrospinal fluid (CSF) spaces (AFMS1); 3 (8.3%) had FMS with loss of the CSF space but no spinal cord distortion (AFMS2); 13 (36.1%) had FMS with flattening of the cervical cord without signal change (AFMS3); and 5 (13.9%) had FMS resulting in cervical cord signal change (AFMS4)."
explanation: Infant MRI cohort shows that most screened infants had foramen magnum stenosis, including many with cord flattening or signal change.
- reference: PMID:38554024
reference_title: "Clinical outcomes and medical management of achondroplasia in Japanese children: A retrospective medical record review of clinical data."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "All patients were monitored by magnetic resonance imaging; 73.0% had foramen magnum stenosis, while 54.1% had Achondroplasia Foramen Magnum Score 3 or 4."
explanation: Independent pediatric cohort confirms that foramen magnum stenosis is a frequent early complication.
- name: Spinal canal stenosis
frequency: FREQUENT
description: >
Cervical and lumbar spinal canal stenosis occur across the lifespan and symptomatic lumbar disease is especially important in adults.
phenotype_term:
preferred_term: Spinal canal stenosis
term:
id: HP:0003416
label: Spinal canal stenosis
evidence:
- reference: PMID:32864841
reference_title: "Natural history of achondroplasia: A retrospective review of longitudinal clinical data."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Cervical and lumbar stenosis were diagnosed in children and adults while, genu varum, elbow contractures, and radial head dislocations were identified during childhood."
explanation: Longitudinal chart review supports spinal stenosis as a cross-lifespan complication affecting both cervical and lumbar regions.
- reference: PMID:32170149
reference_title: "Lumbar spinal stenosis and disc alterations affect the upper lumbar spine in adults with achondroplasia."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Unlike the general population, spinal stenosis and disc degeneration involve the upper part of the lumbar spine in adults with achondroplasia, associated with thoraco-lumbar kyphosis and loss of lumbar lordosis."
explanation: Adult imaging study refines the adult lumbar phenotype by showing upper-lumbar predominance with associated degenerative change.
- reference: ORPHA:15
supports: SUPPORT
snippet: "HP:0003416 | Spinal canal stenosis | Frequent (79-30%)"
explanation: Orphanet classifies spinal canal stenosis as frequent in achondroplasia.
- name: Obstructive sleep apnea
frequency: FREQUENT
description: >
Obstructive sleep apnea is a major respiratory complication in children and can recur later in life.
phenotype_term:
preferred_term: Obstructive sleep apnea
term:
id: HP:0002870
label: Obstructive sleep apnea
evidence:
- reference: PMID:40675782
reference_title: "Sleep-disordered breathing in children with achondroplasia assessed by polysomnography: a retrospective chart review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Sleep-disordered breathing subtypes included obstructive sleep apnoea in 81% (55/68), central sleep apnoea in 3% (2/68), mixed sleep apnoea in 7% (5/68) and primary snoring in 9% (6/68)."
explanation: In a pediatric polysomnography cohort, 55 of 80 children had obstructive sleep apnoea and 5 additional children had mixed apnoea with an obstructive component.
- reference: PMID:32864841
reference_title: "Natural history of achondroplasia: A retrospective review of longitudinal clinical data."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Central sleep apnea and obstructive sleep apnea were present in children, while the diagnosis of obstructive sleep apnea was shown to recur in adulthood."
explanation: Longitudinal review supports both childhood occurrence and adult recurrence of obstructive sleep apnea.
- reference: ORPHA:15
supports: SUPPORT
snippet: "HP:0002870 | Obstructive sleep apnea | Frequent (79-30%)"
explanation: Orphanet classifies obstructive sleep apnea as frequent in achondroplasia.
- name: Central sleep apnea
description: >
Central sleep apnea occurs in some affected children and is part of the sleep-disordered breathing spectrum in achondroplasia.
phenotype_term:
preferred_term: Central sleep apnea
term:
id: HP:0010536
label: Central sleep apnea
evidence:
- reference: PMID:32864841
reference_title: "Natural history of achondroplasia: A retrospective review of longitudinal clinical data."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Central sleep apnea and obstructive sleep apnea were present in children, while the diagnosis of obstructive sleep apnea was shown to recur in adulthood."
explanation: Longitudinal natural-history data explicitly document central sleep apnea in children with achondroplasia.
- reference: PMID:40675782
reference_title: "Sleep-disordered breathing in children with achondroplasia assessed by polysomnography: a retrospective chart review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Sleep-disordered breathing subtypes included obstructive sleep apnoea in 81% (55/68), central sleep apnoea in 3% (2/68), mixed sleep apnoea in 7% (5/68) and primary snoring in 9% (6/68)."
explanation: Polysomnography cohort confirms central sleep apnoea as a measured pediatric sleep phenotype, although much less common than obstructive disease.
- name: Otitis media with effusion
description: >
Otitis media with effusion is a common otologic complication and often leads to repeated ventilation-tube placement.
phenotype_term:
preferred_term: Otitis media with effusion
term:
id: HP:0031353
label: Otitis media with effusion
evidence:
- reference: PMID:39660705
reference_title: "Otologic Manifestations in Patients with Achondroplasia: A Multicenter Study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Fifty-one patients (72.9%) had middle ear effusion at least once."
explanation: Multicenter otology cohort shows otitis media with effusion in most evaluated patients.
- name: Conductive hearing impairment
frequency: FREQUENT
description: >
Hearing loss is common and is usually conductive or mixed rather than purely sensorineural.
phenotype_term:
preferred_term: Conductive hearing impairment
term:
id: HP:0000405
label: Conductive hearing impairment
evidence:
- reference: PMID:39660705
reference_title: "Otologic Manifestations in Patients with Achondroplasia: A Multicenter Study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Among 53 patients who underwent audiometry, 26 showed conductive hearing loss, 2 had mixed-type hearing loss, and 4 had sensorineural hearing loss."
explanation: Pediatric multicenter cohort shows that hearing loss in achondroplasia is usually conductive or mixed.
- reference: PMID:34736503
reference_title: "Hearing loss in Norwegian adults with achondroplasia."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The majority (15/24) had conductive hearing loss, or a combination of conductive and sensorineural hearing loss (8/24)."
explanation: Adult population-based cohort shows conductive or mixed hearing loss remains common beyond childhood.
- reference: ORPHA:15
supports: SUPPORT
snippet: "HP:0000365 | Hearing impairment | Frequent (79-30%)"
explanation: Orphanet classifies hearing impairment as frequent in achondroplasia; conductive is the predominant subtype per PMID evidence.
- name: Obesity
frequency: OCCASIONAL
description: >
Obesity begins in early childhood and remains prevalent across the lifespan.
phenotype_term:
preferred_term: Obesity
term:
id: HP:0001513
label: Obesity
evidence:
- reference: PMID:3228140
reference_title: "Obesity in achondroplasia."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Obesity is a significant and potentially serious health problem in achondroplasia. Body mass indices, weight-to-square of the height ratio (W/H2), and triceps skinfold measurements show that obesity is common. It begins in early childhood and is prevalent at all ages."
explanation: Classic cohort study directly supports obesity as an early and persistent complication.
- reference: ORPHA:15
supports: SUPPORT
snippet: "HP:0001513 | Obesity | Occasional (29-5%)"
explanation: Orphanet classifies obesity as occasional in achondroplasia.
- name: Hydrocephalus
frequency: VERY_RARE
description: >
Hydrocephalus is an occasional but clinically important neurosurgical complication in childhood.
phenotype_term:
preferred_term: Hydrocephalus
term:
id: HP:0000238
label: Hydrocephalus
evidence:
- reference: PMID:33579320
reference_title: "Predictors of cervical myelopathy and hydrocephalus in young children with achondroplasia."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Cervical myelopathy and hydrocephalus occasionally occur in young children with achondroplasia."
explanation: Supports hydrocephalus as a recognized pediatric complication without overstating its frequency.
- reference: PMID:29972438
reference_title: "Natural history of 39 patients with Achondroplasia."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "One patient developed hydrocephalus at 10 years old."
explanation: Natural-history cohort provides direct longitudinal evidence that hydrocephalus can occur during follow-up.
- reference: ORPHA:15
supports: SUPPORT
snippet: "HP:0000238 | Hydrocephalus | Very rare (<4-1%)"
explanation: Orphanet classifies hydrocephalus as very rare in achondroplasia, consistent with its characterization as an occasional complication.
- name: Delayed gross motor development
description: >
Children with achondroplasia show delayed acquisition of gross motor and ambulatory skills.
phenotype_term:
preferred_term: Delayed gross motor development
term:
id: HP:0002194
label: Delayed gross motor development
evidence:
- reference: PMID:22409389
reference_title: "Development in children with achondroplasia: a prospective clinical cohort study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "children with achondroplasia are delayed in development of gross motor and ambulatory skills."
explanation: Prospective developmental cohort directly supports delayed gross motor development.
- reference: PMID:29972438
reference_title: "Natural history of 39 patients with Achondroplasia."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "There was motor developmental delay in 18 patients and speech delay in 16 patients."
explanation: Independent natural-history cohort corroborates developmental delay affecting motor milestones.
- name: Delayed speech and language development
description: >
Speech and language delay is reported in pediatric achondroplasia cohorts.
phenotype_term:
preferred_term: Delayed speech and language development
term:
id: HP:0000750
label: Delayed speech and language development
evidence:
- reference: PMID:29972438
reference_title: "Natural history of 39 patients with Achondroplasia."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "There was motor developmental delay in 18 patients and speech delay in 16 patients."
explanation: Natural-history cohort directly reports speech delay in a substantial subset of patients.
- reference: PMID:22409389
reference_title: "Development in children with achondroplasia: a prospective clinical cohort study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "While delays were seen in development of later communication items, there were fewer delays seen across development of early communication, fine motor, and feeding skills."
explanation: Prospective developmental study supports delayed later communication skill acquisition.
- name: Elbow contracture
description: >
Elbow contractures are recognized childhood orthopedic manifestations.
phenotype_term:
preferred_term: Elbow contracture
term:
id: HP:0034391
label: Elbow contracture
evidence:
- reference: PMID:32864841
reference_title: "Natural history of achondroplasia: A retrospective review of longitudinal clinical data."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Cervical and lumbar stenosis were diagnosed in children and adults while, genu varum, elbow contractures, and radial head dislocations were identified during childhood."
explanation: Longitudinal chart review identifies elbow contractures as a childhood orthopedic phenotype.
- name: Radial head dislocation
description: >
Radial head dislocation is an orthopedic manifestation recognized during childhood.
phenotype_term:
preferred_term: Radial head dislocation
term:
id: HP:0005070
label: Proximal radial head dislocation
evidence:
- reference: PMID:32864841
reference_title: "Natural history of achondroplasia: A retrospective review of longitudinal clinical data."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Cervical and lumbar stenosis were diagnosed in children and adults while, genu varum, elbow contractures, and radial head dislocations were identified during childhood."
explanation: Longitudinal chart review identifies radial head dislocation as a childhood orthopedic phenotype.
- name: Lumbar hyperlordosis
frequency: FREQUENT
description: >
Exaggerated lumbar lordosis is a characteristic spinal deformity in achondroplasia.
phenotype_term:
preferred_term: Lumbar hyperlordosis
term:
id: HP:0002938
label: Lumbar hyperlordosis
evidence:
- reference: ORPHA:15
supports: SUPPORT
snippet: "HP:0002938 | Lumbar hyperlordosis | Frequent (79-30%)"
explanation: Orphanet classifies lumbar hyperlordosis as frequent in achondroplasia.
- name: Brachydactyly
frequency: FREQUENT
description: >
Short fingers are a characteristic hand phenotype in achondroplasia.
phenotype_term:
preferred_term: Brachydactyly
term:
id: HP:0001156
label: Brachydactyly
evidence:
- reference: ORPHA:15
supports: SUPPORT
snippet: "HP:0001156 | Brachydactyly | Frequent (79-30%)"
explanation: Orphanet classifies brachydactyly as frequent in achondroplasia.
- name: Limited elbow extension
frequency: FREQUENT
description: >
Limited elbow extension is a common upper-limb joint restriction in achondroplasia.
phenotype_term:
preferred_term: Limited elbow extension
term:
id: HP:0001377
label: Limited elbow extension
evidence:
- reference: ORPHA:15
supports: SUPPORT
snippet: "HP:0001377 | Limited elbow extension | Frequent (79-30%)"
explanation: Orphanet classifies limited elbow extension as frequent in achondroplasia.
- name: Floppy infant
frequency: FREQUENT
description: >
Infantile hypotonia is frequently observed and contributes to delayed motor milestones.
phenotype_term:
preferred_term: Floppy infant
term:
id: HP:0008947
label: Floppy infant
evidence:
- reference: ORPHA:15
supports: SUPPORT
snippet: "HP:0008947 | Floppy infant | Frequent (79-30%)"
explanation: Orphanet lists floppy infant as frequent in achondroplasia, supporting infantile muscular hypotonia.
- name: Depressed nasal bridge
frequency: FREQUENT
description: >
Depressed nasal bridge is part of the characteristic midface hypoplasia.
phenotype_term:
preferred_term: Depressed nasal bridge
term:
id: HP:0005280
label: Depressed nasal bridge
evidence:
- reference: ORPHA:15
supports: SUPPORT
snippet: "HP:0005280 | Depressed nasal bridge | Frequent (79-30%)"
explanation: Orphanet classifies depressed nasal bridge as frequent in achondroplasia.
- name: Frontal bossing
frequency: FREQUENT
description: >
Frontal bossing is a characteristic craniofacial feature of achondroplasia.
phenotype_term:
preferred_term: Frontal bossing
term:
id: HP:0002007
label: Frontal bossing
evidence:
- reference: ORPHA:15
supports: SUPPORT
snippet: "HP:0002007 | Frontal bossing | Frequent (79-30%)"
explanation: Orphanet classifies frontal bossing as frequent in achondroplasia.
- name: Restrictive ventilatory defect
frequency: OCCASIONAL
description: >
Restrictive lung disease can occur due to thoracic hypoplasia and reduced chest wall compliance.
phenotype_term:
preferred_term: Restrictive ventilatory defect
term:
id: HP:0002091
label: Restrictive ventilatory defect
evidence:
- reference: ORPHA:15
supports: SUPPORT
snippet: "HP:0002091 | Restrictive ventilatory defect | Occasional (29-5%)"
explanation: Orphanet classifies restrictive ventilatory defect as occasional in achondroplasia.
- name: Acanthosis nigricans
frequency: OCCASIONAL
description: >
Acanthosis nigricans is an occasional skin manifestation in achondroplasia.
phenotype_term:
preferred_term: Acanthosis nigricans
term:
id: HP:0000956
label: Acanthosis nigricans
evidence:
- reference: ORPHA:15
supports: SUPPORT
snippet: "HP:0000956 | Acanthosis nigricans | Occasional (29-5%)"
explanation: Orphanet classifies acanthosis nigricans as occasional in achondroplasia.
- name: Knee joint hypermobility
frequency: FREQUENT
description: >
Knee joint hypermobility is a frequent finding contributing to genu varum and gait disturbance.
phenotype_term:
preferred_term: Knee joint hypermobility
term:
id: HP:0045086
label: Knee joint hypermobility
evidence:
- reference: ORPHA:15
supports: SUPPORT
snippet: "HP:0045086 | Knee joint hypermobility | Frequent (79-30%)"
explanation: Orphanet classifies knee joint hypermobility as frequent in achondroplasia.
- name: Hip joint hypermobility
frequency: FREQUENT
description: >
Hip joint hypermobility is a frequent finding in achondroplasia.
phenotype_term:
preferred_term: Hip joint hypermobility
term:
id: HP:0045087
label: Hip joint hypermobility
evidence:
- reference: ORPHA:15
supports: SUPPORT
snippet: "HP:0045087 | Hip joint hypermobility | Frequent (79-30%)"
explanation: Orphanet classifies hip joint hypermobility as frequent in achondroplasia.
- name: Limb undergrowth
frequency: VERY_FREQUENT
description: >
Limb undergrowth is the core skeletal manifestation of achondroplasia, reflecting impaired endochondral ossification of the appendicular skeleton.
phenotype_term:
preferred_term: Limb undergrowth
term:
id: HP:0009826
label: Limb undergrowth
evidence:
- reference: ORPHA:15
supports: SUPPORT
snippet: "HP:0009826 | Limb undergrowth | Very frequent (99-80%)"
explanation: Orphanet classifies limb undergrowth as very frequent in achondroplasia.
genetic:
- name: FGFR3 G380R mutation
association: Causative
notes: >
Over 95% of achondroplasia cases are caused by the c.1138G>A (p.Gly380Arg) mutation
in exon 10 of the FGFR3 gene. A smaller proportion have the c.1138G>C variant
resulting in the same amino acid substitution. The mutation is in the transmembrane
domain of the receptor and causes constitutive activation.
evidence:
- reference: PMID:7847369
reference_title: "Achondroplasia is defined by recurrent G380R mutations of FGFR3."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The homogeneity of mutations in achondroplasia is unprecedented for an autosomal dominant disorder and may explain the relative lack of heterogeneity in the achondroplasia phenotype."
explanation: Study of 154 patients showed that 153 had the same G380R mutation, demonstrating the remarkable genetic homogeneity of achondroplasia.
- reference: ORPHA:15
supports: SUPPORT
snippet: "FGFR3 | fibroblast growth factor receptor 3 | hgnc:3690 | Disease-causing germline mutation(s) (gain of function) in"
explanation: Orphanet confirms FGFR3 gain-of-function germline mutations as the genetic cause of achondroplasia.
variants:
- name: c.1138G>A (p.Gly380Arg)
description: The most common causative mutation, accounting for over 95% of cases.
evidence:
- reference: PMID:7913883
reference_title: "Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Both mutations result in the substitution of an arginine residue for a glycine at position 380 of the mature protein, which is in the transmembrane domain of FGFR3."
explanation: Original discovery paper identifying the specific G380R substitution in the FGFR3 transmembrane domain as the cause of achondroplasia.
- name: FGFR3
gene_term:
preferred_term: FGFR3
term:
id: hgnc:3690
label: FGFR3
association: Pathogenic Variants
evidence:
- reference: CGGV:assertion_0adafa1b-e609-4b99-8e90-f73473b70771-2023-09-28T040000.000Z
reference_title: "FGFR3 / achondroplasia (Definitive)"
supports: SUPPORT
evidence_source: OTHER
snippet: "FGFR3 | HGNC:3690 | achondroplasia | MONDO:0007037 | AD | Definitive"
explanation: ClinGen classifies the FGFR3-achondroplasia gene-disease relationship as definitive with autosomal dominant inheritance.
treatments:
- name: Vosoritide (Voxzogo)
description: >
C-type natriuretic peptide (CNP) analog that counteracts FGFR3 overactivation
by stimulating the NPR-B receptor, promoting endochondral bone growth. FDA approved
in 2021 for children aged 5 years and older with open growth plates. Phase 3
extension data demonstrated sustained growth-promoting effects for up to 6 years,
with a mean additional height gain of 5.75 cm over 3 years compared to untreated controls.
treatment_term:
preferred_term: Vosoritide therapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: vosoritide
term:
id: NCIT:C152918
label: Vosoritide
target_mechanisms:
- target: CNP-NPR2 counter-regulatory pathway
treatment_effect: ACTIVATES
description: >
Vosoritide acts as a CNP analog that activates the endogenous
CNP-NPR2 counter-regulatory pathway opposing FGFR3-MAPK overactivity
in growth plate chondrocytes.
evidence:
- reference: PMID:31269546
reference_title: "C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Vosoritide is a biologic analogue of C-type natriuretic peptide, a potent stimulator of endochondral ossification."
explanation: Clinical trial abstract directly identifies vosoritide as a CNP analog, supporting activation of the endogenous CNP-NPR2 signaling axis.
- reference: PMID:14702637
reference_title: "Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "These results demonstrate that activation of the CNP-GC-B system in endochondral bone formation constitutes a new therapeutic strategy for human achondroplasia."
explanation: Preclinical mouse data directly support activation of the CNP-GC-B/NPR2 pathway as the mechanistic basis for CNP-analog therapy in achondroplasia.
evidence:
- reference: PMID:31269546
reference_title: "C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Treatment resulted in a sustained increase in the annualized growth velocity for up to 42 months."
explanation: This NEJM phase 2 trial demonstrated that vosoritide treatment in children with achondroplasia resulted in sustained increases in growth velocity over 42 months of follow-up.
- reference: PMID:39740666
reference_title: "Sustained growth-promoting effects of vosoritide in children with achondroplasia from an ongoing phase 3 extension study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The mean (SD) differences in annualized growth velocity across each integer age (6-16 years) between treated and untreated children were 1.84 (0.38) cm/year in boys and 1.44 (0.63) cm/year in girls."
explanation: Phase 3 extension study with 119 participants demonstrates that vosoritide provides clinically meaningful growth velocity improvements compared to untreated children across ages 6-16 years.
- reference: PMID:39740666
reference_title: "Sustained growth-promoting effects of vosoritide in children with achondroplasia from an ongoing phase 3 extension study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Vosoritide treatment was well tolerated and had sustained growth-promoting effects in children with achondroplasia treated for up to 6 years."
explanation: Demonstrates long-term safety and sustained efficacy over 6 years of continuous treatment with a favorable safety profile.
- name: Surgical limb lengthening
description: Distraction osteogenesis techniques (Ilizarov, PRECICE) can increase limb length but are controversial due to complications, prolonged treatment duration, and quality of life considerations.
treatment_term:
preferred_term: Limb lengthening surgery
term:
id: MAXO:0000004
label: surgical procedure
- name: Foramen magnum decompression
description: >
Surgical decompression may be required for symptomatic foramen magnum stenosis
with cervicomedullary compression, which can cause central apnea, hypotonia,
or sudden death in infants. Polysomnography is a useful indicator for surgical decision-making.
treatment_term:
preferred_term: Foramen magnum decompression
term:
id: MAXO:0000004
label: surgical procedure
evidence:
- reference: PMID:29959505
reference_title: "Polysomnography as an indicator for cervicomedullary decompression to treat foramen magnum stenosis in achondroplasia."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Three of these patients demonstrated improved sleep respiration soon after surgery, while one required temporary tracheostomy due to bilateral vocal cord paralysis caused by compression during intratracheal intubation."
explanation: Clinical evidence showing that cervicomedullary decompression improves sleep-related respiratory disturbance in achondroplasia patients with foramen magnum stenosis.
- name: Management of spinal stenosis
description: Progressive lumbar spinal stenosis is common in adults and may require laminectomy for symptomatic relief of neurogenic claudication.
treatment_term:
preferred_term: Spinal surgery
term:
id: MAXO:0000004
label: surgical procedure
animal_models:
- species: Mouse
genotype: Fgfr3 G380R knock-in
description: >
Mouse models carrying the equivalent FGFR3 gain-of-function mutation recapitulate
the skeletal phenotype of achondroplasia, including dwarfism, narrowed growth plates,
impaired cranial base synchondroses, foramen magnum formation defects, and altered
trabecular and cortical bone mineral density.
associated_phenotypes:
- Rhizomelic dwarfism
- Narrowed growth plates
- Premature cranial base synchondrosis closure
- Foramen magnum stenosis
- Altered bone mineralization
evidence:
- reference: PMID:32795681
reference_title: "Novel therapeutic approaches for the treatment of achondroplasia."
supports: SUPPORT
evidence_source: OTHER
snippet: "This review provides a brief overview of the preclinical mouse models of achondroplasia that have led to new, non-surgical therapeutic strategies being assessed and applied to children with achondroplasia through pioneering clinical trials."
explanation: Review summarizing how FGFR3 mouse models recapitulate the achondroplasia phenotype and have served as the foundation for developing targeted therapies.
- species: Mouse
genotype: Fgfr3 G380R with CNP transgene overexpression in chondrocytes
description: >
Targeted overexpression of C-type natriuretic peptide in chondrocytes of FGFR3
mutant mice counteracted dwarfism by correcting decreased extracellular matrix
synthesis through inhibition of the MAPK pathway. This model provided the critical
proof-of-concept for vosoritide therapy.
associated_phenotypes:
- Rescue of bone shortening
- Restored extracellular matrix synthesis
evidence:
- reference: PMID:14702637
reference_title: "Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "targeted overexpression of CNP in chondrocytes counteracts dwarfism in a mouse model of achondroplasia with activated fibroblast growth factor receptor 3 (FGFR-3) in the cartilage."
explanation: Landmark Nature Medicine study demonstrating that CNP overexpression rescues the achondroplasia phenotype in mice, providing proof-of-concept for CNP analog therapy.
- species: Mouse
genotype: Constitutively active MEK1 driven by Col2a1 promoter in chondrocytes
description: >
Transgenic mice expressing constitutively active MEK1 in chondrocytes exhibit
achondroplasia-like dwarfism with incomplete chondrocyte hypertrophy and delayed
endochondral ossification, establishing that the MAPK pathway is the key effector
of FGFR3-mediated growth inhibition. MEK1 activation rescues the skeletal overgrowth
of Fgfr3-deficient mice.
associated_phenotypes:
- Achondroplasia-like dwarfism
- Incomplete chondrocyte hypertrophy
- Delayed endochondral ossification
- Reduced collagen X in cranial base
evidence:
- reference: PMID:14871928
reference_title: "Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "We generated transgenic mice that express a constitutively active mutant of MEK1 in chondrocytes. These mice showed a dwarf phenotype similar to achondroplasia, the most common human dwarfism, caused by activating mutations in FGFR3."
explanation: Direct evidence that constitutive MAPK activation in chondrocytes is sufficient to produce achondroplasia-like skeletal abnormalities, demonstrating the centrality of this pathway.
- reference: PMID:14871928
reference_title: "Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "Expression of a constitutively active mutant of MEK1 in chondrocytes of Fgfr3-deficient mice inhibited skeletal overgrowth, strongly suggesting that regulation of bone growth by FGFR3 is mediated at least in part by the MAPK pathway."
explanation: Epistasis experiment showing that MEK1 activation rescues the Fgfr3-null phenotype, providing strong genetic evidence that MAPK mediates FGFR3 effects on bone growth.
computational_models:
- name: In Silico Characterization of FGFR3 p.G380R Mutation
description: >-
Computational structural analysis of the achondroplasia-causing p.G380R substitution
in the FGFR3 transmembrane domain using multiple bioinformatics tools. The mutation
adversely affects dimerization efficiency and overall stability of FGFR3, leading
to constitutive receptor activation and uncontrolled negative bone growth regulation.
model_type: STRUCTURAL_PREDICTION
publication: PMID:28679403
findings:
- statement: p.G380R mutation adversely affects FGFR3 transmembrane domain dimerization and stability
- statement: Constitutive FGFR3 activation from transmembrane domain mutation leads to negative bone growth regulation
evidence:
- reference: PMID:28679403
reference_title: "Identification and in silico characterization of p.G380R substitution in FGFR3, associated with achondroplasia in a non-consanguineous Pakistani family."
supports: SUPPORT
evidence_source: COMPUTATIONAL
snippet: "In silico studies of the mutant FGFR3 protein predicted to adversely affect the stability of FGFR3 protein."
explanation: Computational structural analysis explains how the G380R mutation destabilizes FGFR3, contributing to achondroplasia pathogenesis.
- reference: PMID:28679403
reference_title: "Identification and in silico characterization of p.G380R substitution in FGFR3, associated with achondroplasia in a non-consanguineous Pakistani family."
supports: SUPPORT
evidence_source: COMPUTATIONAL
snippet: "Mutation in the transmembrane domain may adversely affect the dimerization efficiency and overall stability of the FGFR3, leading to a constitutively active protein."
explanation: Structural modeling predicts constitutive FGFR3 activation from altered dimerization, the key molecular mechanism in achondroplasia.
notes: >
Key clinical features include the rhizomelic pattern of limb shortening, relative
macrocephaly with frontal bossing and midface hypoplasia, trident hand configuration,
thoracolumbar kyphosis in infancy, and genu varum. Major complications include
foramen magnum stenosis with risk of sudden death in infancy, progressive spinal
stenosis, obstructive sleep apnea, recurrent otitis media, hydrocephalus, and
obesity. Intelligence is normal. The availability of
vosoritide represents a paradigm shift in treatment, demonstrating that targeting
the underlying molecular defect can improve growth outcomes. FGFR3-selective inhibitors
(e.g., TYRA-300, infigratinib) are under preclinical and clinical investigation as
alternative therapeutic strategies.
datasets:
references:
- reference: DOI:10.1093/hmg/ddn339
title: FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway
findings: []
- reference: DOI:10.1172/jci.insight.168796
title: Hypochondroplasia gain-of-function mutation in FGFR3 causes defective bone mineralization in mice
findings: []
- reference: DOI:10.1172/jci.insight.189307
title: TYRA-300, an FGFR3-selective inhibitor, promotes bone growth in two FGFR3-driven models of chondrodysplasia
findings: []
- reference: DOI:10.1177/00368504211003782
title: Rationale, design, and methods of a randomized, controlled, open-label clinical trial with open-label extension to investigate the safety of vosoritide in infants, and young children with achondroplasia at risk of requiring cervicomedullary decompression surgery
findings: []
Date: 2026-04-18 Curator: Codex Issue: monarch-initiative/dismech#1449
Focused only on strengthening kb/disorders/Achondroplasia.yaml phenotype coverage.
Priority was given to cohort, natural-history, and complication-specific PubMed
abstracts that could support exact quoted snippets for phenotype assertions.
VERY_FREQUENT/FREQUENT claims without explicit evidence.HP:0008905 RhizomeliaHP:0011220 Prominent foreheadHP:0031353 Otitis media with effusionHP:0000405 Conductive hearing impairmentHP:0002194 Delayed gross motor developmentHP:0000750 Delayed speech and language developmentLumbar hyperlordosis and brachydactyly were not retained as standalone phenotypes because the current source set did not provide sufficiently direct abstract-level support for a clean, evidence-backed entry.
Disease Pathophysiology Research Report
Target Disease - Disease Name: Achondroplasia - MONDO ID: MONDO:0009061 - Category: Mendelian
Pathophysiology description Achondroplasia is caused by germline gain-of-function variants in FGFR3 that increase receptor autophosphorylation and downstream signaling in growth-plate chondrocytes, leading to impaired endochondral ossification and disproportionate short stature (rhizomelic limb shortening) (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2). Constitutive activation of the MAPK/ERK cascade and STAT signaling downstream of FGFR3 suppresses chondrocyte proliferation and perturbs the transition from proliferative to hypertrophic zones, with secondary effects on extracellular-matrix (ECM) organization and mineralization (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2, starrett2025tyra300anfgfr3selective pages 1-2). A hallmark developmental mechanism is premature closure of cranial-base synchondroses and fusion of ossification centers driven by FGFR3–MAPK signaling, which narrows the foramen magnum and contributes to cervicomedullary compression risk in infancy and to spinal canal stenosis later in life (matsushita2009fgfr3promotessynchondrosis pages 1-2, savarirayan2021rationaledesignand pages 16-19). Counter-regulatory natriuretic peptide signaling (CNP–NPR2) physiologically antagonizes FGFR3–MAPK activity, providing the rationale for CNP analog therapy to restore growth-plate function (savarirayan2021rationaledesignand pages 16-19, starrett2025tyra300anfgfr3selective pages 1-2).
Selected direct quotes supporting core mechanisms - “FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway.” (Human Molecular Genetics, Oct 2009; https://doi.org/10.1093/hmg/ddn339) (matsushita2009fgfr3promotessynchondrosis pages 1-2) - “FGFR3 is highly expressed in proliferative zone chondrocytes… Downstream signaling reported here includes activation of STAT1, ERK1/2, and p38 MAPK branches.” (JCI Insight, Apr 2025; https://doi.org/10.1172/jci.insight.189307) (starrett2025tyra300anfgfr3selective pages 1-2) - “FGFR3 [GOF] increases trans-autophosphorylation… and [is] a negative regulator of bone growth” with impaired cranial base synchondrosis and foramen magnum development in vivo (JCI Insight, Jun 2023; https://doi.org/10.1172/jci.insight.168796) (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2)
Recent developments and latest research (emphasis 2023–2024) - Growth-plate and cranial-base biology in FGFR3 GOF: A 2023 in vivo study of an FGFR3 GOF model reported progressive dwarfism, impaired cranial-base synchondroses, foramen magnum formation defects, and age-related alterations in long-bone trabecular versus cortical mineral density, emphasizing multi-compartment skeletal involvement (JCI Insight, Jun 2023; https://doi.org/10.1172/jci.insight.168796) (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2). - Synchondrosis closure mechanism: Foundational work demonstrates FGFR3–MAPK drives premature synchondrosis closure and fusion of ossification centers, mechanistically linking to foramen magnum stenosis risk (Human Molecular Genetics, Oct 2009; https://doi.org/10.1093/hmg/ddn339) (matsushita2009fgfr3promotessynchondrosis pages 1-2). - Targeted inhibition of FGFR3: An FGFR3-selective inhibitor (TYRA-300) increased long-bone and skull growth and improved foramen magnum morphology in FGFR3-mutant mice, with histologic evidence of increased chondrocyte proliferation and differentiation (JCI Insight, Apr 2025; https://doi.org/10.1172/jci.insight.189307) (starrett2025tyra300anfgfr3selective pages 1-2). The same synthesis cites oral FGFR inhibitors including infigratinib as under clinical evaluation in achondroplasia, with 2024 reporting noted, though without quantitative outcomes in the cited text (starrett2025tyra300anfgfr3selective pages 14-15, starrett2025tyra300anfgfr3selective pages 15-16). - CNP analogs and early-life architecture: Clinical trial rationale articulates that vosoritide (a CNP analog) may improve growth at the foramen magnum and spinal canal in infants at risk, aligning with the CNP–NPR2 pathway’s antagonism of FGFR3–MAPK signaling (Science Progress, Jan 2021; https://doi.org/10.1177/00368504211003782) (savarirayan2021rationaledesignand pages 16-19).
Current applications and real-world implementations - CNP analog therapy: Vosoritide is in clinical use to counteract overactive FGFR3 signaling; infant/young-child trials are designed to test improvement of foramen magnum and spinal canal growth, with the Achondroplasia Foramen Magnum Score guiding enrollment (Science Progress, Jan 2021; https://doi.org/10.1177/00368504211003782) (savarirayan2021rationaledesignand pages 16-19). While this protocol outlines potential benefits, quantitative clinical outcomes specific to foramen magnum/spinal canal growth are not provided in the cited text and remain an area of ongoing evaluation (savarirayan2021rationaledesignand pages 16-19). - FGFR3 inhibition: Preclinical FGFR3-selective inhibition (TYRA-300) demonstrated increased bone growth and improved cranial-base and vertebral parameters in FGFR3-driven models, supporting translation of FGFR3 inhibitors (JCI Insight, Apr 2025; https://doi.org/10.1172/jci.insight.189307) (starrett2025tyra300anfgfr3selective pages 1-2). References within this source note clinical exploration of infigratinib in children; however, specific efficacy statistics are not present in the excerpted evidence (starrett2025tyra300anfgfr3selective pages 14-15, starrett2025tyra300anfgfr3selective pages 15-16). - Ligand decoy strategy: Soluble FGFR3 decoys (e.g., recifercept-like) are referenced as approaches that restore bone growth in mouse models; clinical details are not quantified within the provided evidence (JCI Insight synthesis, Apr 2025; https://doi.org/10.1172/jci.insight.189307) (starrett2025tyra300anfgfr3selective pages 14-15, starrett2025tyra300anfgfr3selective pages 15-16).
Relevant statistics and data from recent studies - In vivo mineralization and skeletal patterning: In the FGFR3 GOF murine model, long-bone and vertebral trabecular bone mineral density decreased while cortical density increased with age, and cranial-base synchondroses impairment led to foramen magnum formation defects (JCI Insight, Jun 2023; https://doi.org/10.1172/jci.insight.168796) (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2). - Mechanistic necessity of MAPK in cranial base pathology: Experimental perturbation of FGFR3–MAPK in chondrocytes accelerates synchondrosis closure and ossification center fusion, supporting a pathogenic sequence from signaling dysregulation to anatomic stenoses (Human Molecular Genetics, Oct 2009; https://doi.org/10.1093/hmg/ddn339) (matsushita2009fgfr3promotessynchondrosis pages 1-2).
Core Pathophysiology - Primary mechanisms: FGFR3 gain-of-function increases receptor activity, driving MAPK/ERK and STAT pathways that constrain chondrocyte proliferation and disturb hypertrophic differentiation and ECM assembly, thereby limiting longitudinal growth (JCI Insight, Jun 2023; https://doi.org/10.1172/jci.insight.168796) (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2). In cranial base and spine, MAPK-mediated premature synchondrosis closure links molecular activation to foramen magnum and spinal canal stenosis (Human Molecular Genetics, Oct 2009; https://doi.org/10.1093/hmg/ddn339) (matsushita2009fgfr3promotessynchondrosis pages 1-2). - Dysregulated pathways: MAPK/ERK, STAT1 (and related STAT branches), and p38 MAPK are activated in growth-plate chondrocytes under FGFR3 GOF; CNP–NPR2 signaling negatively regulates MAPK and can counterbalance FGFR3 effects (JCI Insight, Apr 2025; https://doi.org/10.1172/jci.insight.189307; Science Progress, Jan 2021; https://doi.org/10.1177/00368504211003782) (starrett2025tyra300anfgfr3selective pages 1-2, savarirayan2021rationaledesignand pages 16-19). - Cellular processes affected: Reduced chondrocyte proliferation, altered cell-cycle regulation, impaired hypertrophic differentiation, disrupted columnar organization, abnormal ECM composition/mineralization, and abnormal ossification-center fusion (JCI Insight, Jun 2023; Human Molecular Genetics, Oct 2009) (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2, matsushita2009fgfr3promotessynchondrosis pages 1-2).
Key Molecular Players - Genes/Proteins (HGNC): FGFR3; STAT1; MAPK1 (ERK2); MAPK3 (ERK1); p38 MAPKs; NPPC (CNP); NPR2; ECM markers including COL10A1 (type X collagen) and ACAN (aggrecan) (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2, starrett2025tyra300anfgfr3selective pages 1-2, matsushita2009fgfr3promotessynchondrosis pages 1-2). - Chemical Entities (CHEBI): C-type natriuretic peptide analogs (vosoritide); small-molecule FGFR3 inhibitors (e.g., FGFR tyrosine kinase inhibitors); soluble FGFR3 decoys (protein biologics) (savarirayan2021rationaledesignand pages 16-19, starrett2025tyra300anfgfr3selective pages 1-2, starrett2025tyra300anfgfr3selective pages 14-15, starrett2025tyra300anfgfr3selective pages 15-16). - Cell Types (CL): Growth-plate chondrocytes (resting, proliferative, hypertrophic); osteoblasts adjacent to synchondroses (starrett2025tyra300anfgfr3selective pages 1-2, matsushita2009fgfr3promotessynchondrosis pages 1-2). - Anatomical Locations (UBERON): Epiphyseal growth plate of long bones; cranial-base synchondroses; foramen magnum; vertebral growth plates and spinal canal (matsushita2009fgfr3promotessynchondrosis pages 1-2, loisay2023hypochondroplasiagainoffunctionmutation pages 1-2).
Biological Processes (GO terms, disrupted) - MAPK cascade; regulation of chondrocyte proliferation; regulation of chondrocyte differentiation; endochondral ossification; extracellular matrix organization; ossification-center fusion; negative regulation of MAPK cascade by natriuretic peptide signaling (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2, matsushita2009fgfr3promotessynchondrosis pages 1-2, starrett2025tyra300anfgfr3selective pages 1-2, savarirayan2021rationaledesignand pages 16-19).
Cellular Components (GO terms) - Plasma membrane (FGFR3 receptor); cytoplasm and nucleus (downstream signaling effectors, STAT1/ERK); extracellular matrix (cartilage ECM; hypertrophic matrix); synchondrosis cartilaginous plates (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2, matsushita2009fgfr3promotessynchondrosis pages 1-2, starrett2025tyra300anfgfr3selective pages 1-2).
Disease Progression: sequence of events - Initiating lesion: FGFR3 GOF mutation → increased receptor autophosphorylation and activation in proliferative-zone chondrocytes (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2, starrett2025tyra300anfgfr3selective pages 1-2). - Signaling dysregulation: Hyperactivation of MAPK/ERK and STAT axes; repression of chondrocyte proliferation and altered maturation toward hypertrophy; ECM disorganization/mineralization defects (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2, starrett2025tyra300anfgfr3selective pages 1-2). - Tissue-level consequences: Narrowed and shortened growth plates; premature cranial-base synchondrosis closure; foramen magnum undergrowth; altered vertebral growth and intervertebral architecture (matsushita2009fgfr3promotessynchondrosis pages 1-2, loisay2023hypochondroplasiagainoffunctionmutation pages 1-2, starrett2025tyra300anfgfr3selective pages 1-2). - Clinical manifestations: Infant risk of cervicomedullary compression due to foramen magnum stenosis; later-life risk of spinal canal stenosis; disproportionate short stature with macrocephaly and midface retrusion (savarirayan2021rationaledesignand pages 16-19, starrett2025tyra300anfgfr3selective pages 1-2).
Phenotypic Manifestations (HP terms) - Disproportionate short stature (HP:0001510); Rhizomelia (HP:0000919); Macrocephaly (HP:0000256); Midface retrusion (HP:0011800); Foramen magnum stenosis (HP:0004923); Spinal canal stenosis (HP:0003416) (supported mechanistically and phenotypically by cited mechanistic and preclinical/clinical rationale sources) (matsushita2009fgfr3promotessynchondrosis pages 1-2, loisay2023hypochondroplasiagainoffunctionmutation pages 1-2, savarirayan2021rationaledesignand pages 16-19, starrett2025tyra300anfgfr3selective pages 1-2).
Expert opinions and analysis from authoritative sources - Mechanistic consensus: Studies converge that FGFR3 is a negative regulator of bone growth whose GOF drives MAPK-mediated premature synchondrosis closure and growth-plate dysfunction, recapitulating key clinical features (Human Molecular Genetics, 2009; JCI Insight, 2023) (matsushita2009fgfr3promotessynchondrosis pages 1-2, loisay2023hypochondroplasiagainoffunctionmutation pages 1-2). - Therapeutic strategy consensus: Counteracting FGFR3 signaling via CNP–NPR2 pathway augmentation (vosoritide) or direct FGFR3 inhibition are coherent, mechanism-based strategies; timing before synchondrosis closure is likely critical for cranial-base outcomes (Science Progress, 2021; JCI Insight, 2025) (savarirayan2021rationaledesignand pages 16-19, starrett2025tyra300anfgfr3selective pages 1-2).
Evidence items with URLs and publication dates - Loisay et al., JCI Insight, Jun 2023. “Hypochondroplasia gain-of-function mutation in FGFR3 causes defective bone mineralization in mice.” URL: https://doi.org/10.1172/jci.insight.168796 (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2). - Matsushita et al., Human Molecular Genetics, Oct 2009. “FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway.” URL: https://doi.org/10.1093/hmg/ddn339 (matsushita2009fgfr3promotessynchondrosis pages 1-2). - Starrett et al., JCI Insight, Apr 2025. “TYRA-300, an FGFR3-selective inhibitor, promotes bone growth in two FGFR3-driven models of chondrodysplasia.” URL: https://doi.org/10.1172/jci.insight.189307 (starrett2025tyra300anfgfr3selective pages 1-2). - Savarirayan et al., Science Progress, Jan 2021. “Rationale, design, and methods… vosoritide in infants… at risk of cervicomedullary decompression surgery.” URL: https://doi.org/10.1177/00368504211003782 (savarirayan2021rationaledesignand pages 16-19). - Integrated therapeutic context and 2024 reporting notes on infigratinib and decoy strategies are cited within the 2025 JCI Insight synthesis (Starrett et al.), but without quantitative outcomes in our provided evidence (starrett2025tyra300anfgfr3selective pages 14-15, starrett2025tyra300anfgfr3selective pages 15-16).
Embedded evidence table | Mechanism/Process | Evidence summary | Key molecules (HGNC symbols) | Pathway/GO term (names only) | Cellular component | Cell type | Tissue/Anatomical site | Therapeutic modulation/agent | Source (citation id; URL; publication month/year) | |---|---|---|---|---|---|---|---|---| | FGFR3 gain-of-function (GOF) signaling | GOF mutations increase FGFR3 autophosphorylation activating MAPK/ERK and STAT pathways that inhibit chondrocyte proliferation and alter differentiation. | FGFR3, STAT1, MAPK1, MAPK3 | MAPK cascade; STAT signaling; negative regulation of chondrocyte proliferation | Plasma membrane; cytoplasm; nucleus | Chondrocyte (proliferative zone) | Growth plate cartilage (epiphyseal growth plate) | FGFR inhibitors (e.g., infigratinib), soluble FGFR3 decoys (recifercept) | (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2, matsushita2009fgfr3promotessynchondrosis pages 1-2); https://doi.org/10.1172/jci.insight.168796 ; https://doi.org/10.1093/hmg/ddn339 ; Jun 2023; Oct 2009 | | Growth-plate zonal effects (resting→proliferative→hypertrophic) | Excess FGFR3 signaling disrupts the resting→proliferative→hypertrophic transition, reducing proliferation and impairing hypertrophic differentiation and ECM organization. | FGFR3, SOX9, COL10A1 | Regulation of chondrocyte differentiation; endochondral ossification | Extracellular matrix; growth-plate cartilage | Chondrocyte (resting/proliferative/hypertrophic) | Epiphyseal growth plate | CNP analogs (vosoritide) to counteract FGFR3; FGFR3 inhibitors | (starrett2025tyra300anfgfr3selective pages 1-2, loisay2023hypochondroplasiagainoffunctionmutation pages 1-2); https://doi.org/10.1172/jci.insight.189307 ; https://doi.org/10.1172/jci.insight.168796 ; Apr 2025; Jun 2023 | | Cranial base synchondrosis closure → foramen magnum stenosis | FGFR3–MAPK activation accelerates synchondrosis closure and ossification-center fusion, producing premature cranial base fusion and foramen magnum narrowing. | FGFR3, MAPK1, MAPK3, BMP4 | MAPK cascade; ossification; fusion of ossification centers | Synchondrosis cartilage; extracellular region | Chondrocytes; osteoblasts adjacent to synchondroses | Cranial base; foramen magnum | Early growth-promoting therapy (vosoritide) and FGFR3-targeting agents to prevent/modify premature closure | (matsushita2009fgfr3promotessynchondrosis pages 1-2, loisay2023hypochondroplasiagainoffunctionmutation pages 1-2); https://doi.org/10.1093/hmg/ddn339 ; https://doi.org/10.1172/jci.insight.168796 ; Oct 2009; Jun 2023 | | Vertebral growth abnormalities → spinal canal stenosis | Premature fusion and altered vertebral growth (FGFR3-driven) contribute to narrowed spinal canal and symptomatic lumbar/cervicomedullary stenosis across the lifespan. | FGFR3, MAPK1, MAPK3 | Regulation of bone growth; endochondral ossification | Vertebral growth plate; intervertebral disc | Chondrocytes; nucleus pulposus/annulus fibrosus cells | Spinal canal; vertebral bodies; intervertebral discs | Multidisciplinary monitoring; surgical decompression; investigational early medical therapy (vosoritide) | (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2, savarirayan2021rationaledesignand pages 16-19); https://doi.org/10.1172/jci.insight.168796 ; https://doi.org/10.1177/00368504211003782 ; Jun 2023; Jan 2021 | | ECM composition and chondrocyte hypertrophy abnormalities | FGFR3 activation alters ECM molecule expression and chondrocyte hypertrophy (e.g., COL10A1, ACAN), disrupting columnar organization and mineralization. | COL10A1, ACAN, FGFR3 | Extracellular matrix organization; collagen fibril organization | Extracellular matrix; mineralized matrix | Hypertrophic chondrocyte | Growth plate cartilage; metaphysis | Agents restoring differentiation/ECM organization (CNP analogs, soluble FGFR3, FGFR3 inhibitors) | (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2, starrett2025tyra300anfgfr3selective pages 1-2); https://doi.org/10.1172/jci.insight.168796 ; https://doi.org/10.1172/jci.insight.189307 ; Jun 2023; Apr 2025 | | CNP–NPR2 counter-regulation of FGFR3 | CNP–NPR2 signaling antagonizes FGFR3–MAPK activity to stimulate endochondral growth, providing the mechanistic rationale for CNP analog therapy (vosoritide). | NPPC (CNP), NPR2, FGFR3 | Natriuretic peptide receptor signaling pathway; negative regulation of MAPK cascade | Extracellular region; plasma membrane | Growth-plate chondrocyte | Growth plate cartilage | Vosoritide (CNP analog) — clinical development and infant/child trial programs | (savarirayan2021rationaledesignand pages 16-19, starrett2025tyra300anfgfr3selective pages 1-2); https://doi.org/10.1177/00368504211003782 ; https://doi.org/10.1172/jci.insight.189307 ; Jan 2021; Apr 2025 | | FGFR3-selective inhibition (TYRA-300) — preclinical | A selective FGFR3 inhibitor (TYRA-300) increased naso‑anal and long-bone lengths and improved skull/foramen magnum morphology in FGFR3-mutant mouse models. | FGFR3 | MAPK cascade; regulation of chondrocyte proliferation | Plasma membrane; growth plate cartilage | Chondrocyte | Long-bone growth plate; skull; vertebrae | TYRA-300 (FGFR3-selective small-molecule inhibitor; preclinical) | (starrett2025tyra300anfgfr3selective pages 1-2); https://doi.org/10.1172/jci.insight.189307 ; Apr 2025 |
Table: A concise evidence-linked table mapping core pathophysiology mechanisms in achondroplasia to key molecules, cellular/tissue locations, GO-style pathway names, and current targeted interventions with source citations for rapid reference.
Gene/protein annotations with ontology terms - FGFR3 (HGNC:3689) — negative regulation of chondrocyte proliferation; MAPK cascade; localization: plasma membrane; cell type: growth-plate chondrocyte; anatomy: epiphyseal growth plate, cranial base synchondroses (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2, matsushita2009fgfr3promotessynchondrosis pages 1-2, starrett2025tyra300anfgfr3selective pages 1-2). - STAT1 (HGNC:11362) — STAT signaling; nucleus/cytoplasm; downstream of FGFR3 in chondrocytes (starrett2025tyra300anfgfr3selective pages 1-2, loisay2023hypochondroplasiagainoffunctionmutation pages 1-2). - MAPK1/MAPK3 (ERK2/ERK1; HGNC:6871/6877) — MAPK cascade; cytoplasm/nucleus; mediators of FGFR3 effects on proliferation/differentiation and synchondrosis closure (matsushita2009fgfr3promotessynchondrosis pages 1-2, starrett2025tyra300anfgfr3selective pages 1-2). - NPPC (CNP; HGNC:7947) / NPR2 (HGNC:7943) — natriuretic peptide receptor signaling; negative regulation of MAPK; extracellular/plasma membrane; cell type: chondrocyte (savarirayan2021rationaledesignand pages 16-19, starrett2025tyra300anfgfr3selective pages 1-2). - COL10A1 (HGNC:2214); ACAN (HGNC:320) — ECM organization and hypertrophic cartilage matrix (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2, starrett2025tyra300anfgfr3selective pages 1-2).
Cell type involvement (CL terms) - Chondrocyte (growth plate; resting/proliferative/hypertrophic) — CL:0000138 and subtypes; principal site of FGFR3 overactivation (starrett2025tyra300anfgfr3selective pages 1-2, loisay2023hypochondroplasiagainoffunctionmutation pages 1-2, matsushita2009fgfr3promotessynchondrosis pages 1-2). - Osteoblasts adjacent to synchondroses — involved in ossification-center fusion (matsushita2009fgfr3promotessynchondrosis pages 1-2).
Anatomical locations (UBERON terms) - Epiphyseal growth plate (UBERON:0002515); Long bone (UBERON:0002495); Cranial base synchondroses (UBERON:0011158, regionally); Foramen magnum (UBERON:0010245); Vertebral body and spinal canal (UBERON:0002412, UBERON:0004469) (matsushita2009fgfr3promotessynchondrosis pages 1-2, loisay2023hypochondroplasiagainoffunctionmutation pages 1-2, starrett2025tyra300anfgfr3selective pages 1-2).
Chemical entities (CHEBI) - Vosoritide (CNP analog; peptide therapeutic; CHEBI class: peptide drug) — enhances NPR2 signaling to antagonize FGFR3–MAPK (savarirayan2021rationaledesignand pages 16-19). - FGFR inhibitors (e.g., infigratinib; small-molecule tyrosine kinase inhibitor; CHEBI class: kinase inhibitor) — reduce FGFR3 signaling (contextualized in JCI Insight synthesis) (starrett2025tyra300anfgfr3selective pages 14-15, starrett2025tyra300anfgfr3selective pages 15-16). - Soluble FGFR3 decoys (protein biologics) — ligand trap to reduce FGFR3 activation (starrett2025tyra300anfgfr3selective pages 14-15, starrett2025tyra300anfgfr3selective pages 15-16).
Limitations of current evidence - While multiple sources document mechanism and preclinical efficacy, the provided evidence set does not include detailed 2023–2024 quantitative outcomes for vosoritide’s effects on foramen magnum/spinal canal dimensions or for pediatric infigratinib; these remain active areas of investigation, and readers should consult current trial reports for updated statistics (savarirayan2021rationaledesignand pages 16-19, starrett2025tyra300anfgfr3selective pages 14-15, starrett2025tyra300anfgfr3selective pages 15-16).
References (with citations) - Loisay L, et al. JCI Insight. Jun 2023. URL: https://doi.org/10.1172/jci.insight.168796 (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2). - Matsushita T, et al. Human Molecular Genetics. Oct 2009. URL: https://doi.org/10.1093/hmg/ddn339 (matsushita2009fgfr3promotessynchondrosis pages 1-2). - Starrett JH, et al. JCI Insight. Apr 2025. URL: https://doi.org/10.1172/jci.insight.189307 (starrett2025tyra300anfgfr3selective pages 1-2, starrett2025tyra300anfgfr3selective pages 14-15, starrett2025tyra300anfgfr3selective pages 15-16). - Savarirayan R, et al. Science Progress. Jan 2021. URL: https://doi.org/10.1177/00368504211003782 (savarirayan2021rationaledesignand pages 16-19).
References
(loisay2023hypochondroplasiagainoffunctionmutation pages 1-2): Léa Loisay, Davide Komla-Ebri, Anne Morice, Yann Heuzé, Camille Viaut, Amélie de La Seiglière, Nabil Kaci, Danny Chan, Audrey Lamouroux, Geneviève Baujat, J.H. Duncan Bassett, Graham R. Williams, and Laurence Legeai-Mallet. Hypochondroplasia gain-of-function mutation in fgfr3 causes defective bone mineralization in mice. JCI Insight, Jun 2023. URL: https://doi.org/10.1172/jci.insight.168796, doi:10.1172/jci.insight.168796. This article has 9 citations and is from a domain leading peer-reviewed journal.
(starrett2025tyra300anfgfr3selective pages 1-2): Jacqueline H. Starrett, Clara Lemoine, Matthias Guillo, Chantal Fayad, Nabil Kaci, Melissa Neal, Emily A. Pettitt, Melissandre Pache, Qing Ye, My Chouinard, Eric L. Allen, Geneviève Baujat, Robert L. Hudkins, Michael B. Bober, Todd Harris, Ronald V. Swanson, and Laurence Legeai-Mallet. Tyra-300, an fgfr3-selective inhibitor, promotes bone growth in two fgfr3-driven models of chondrodysplasia. JCI Insight, Apr 2025. URL: https://doi.org/10.1172/jci.insight.189307, doi:10.1172/jci.insight.189307. This article has 2 citations and is from a domain leading peer-reviewed journal.
(matsushita2009fgfr3promotessynchondrosis pages 1-2): T. Matsushita, W. R. Wilcox, Y. Y. Chan, A. Kawanami, H. Bukulmez, G. Balmes, P. Krejci, P. B. Mekikian, K. Otani, I. Yamaura, M. L. Warman, D. Givol, and S. Murakami. Fgfr3 promotes synchondrosis closure and fusion of ossification centers through the mapk pathway. Human Molecular Genetics, 18:227-240, Oct 2009. URL: https://doi.org/10.1093/hmg/ddn339, doi:10.1093/hmg/ddn339. This article has 165 citations and is from a domain leading peer-reviewed journal.
(savarirayan2021rationaledesignand pages 16-19): Ravi Savarirayan, Melita Irving, Wirginia Maixner, Dominic Thompson, Amaka C Offiah, Daniel JA Connolly, Ashok Raghavan, James Powell, Marcin Kronhardt, George Jeha, Sajda Ghani, Elena Fisheleva, and Jonathan RS Day. Rationale, design, and methods of a randomized, controlled, open-label clinical trial with open-label extension to investigate the safety of vosoritide in infants, and young children with achondroplasia at risk of requiring cervicomedullary decompression surgery. Science Progress, Jan 2021. URL: https://doi.org/10.1177/00368504211003782, doi:10.1177/00368504211003782. This article has 34 citations and is from a poor quality or predatory journal.
(starrett2025tyra300anfgfr3selective pages 14-15): Jacqueline H. Starrett, Clara Lemoine, Matthias Guillo, Chantal Fayad, Nabil Kaci, Melissa Neal, Emily A. Pettitt, Melissandre Pache, Qing Ye, My Chouinard, Eric L. Allen, Geneviève Baujat, Robert L. Hudkins, Michael B. Bober, Todd Harris, Ronald V. Swanson, and Laurence Legeai-Mallet. Tyra-300, an fgfr3-selective inhibitor, promotes bone growth in two fgfr3-driven models of chondrodysplasia. JCI Insight, Apr 2025. URL: https://doi.org/10.1172/jci.insight.189307, doi:10.1172/jci.insight.189307. This article has 2 citations and is from a domain leading peer-reviewed journal.
(starrett2025tyra300anfgfr3selective pages 15-16): Jacqueline H. Starrett, Clara Lemoine, Matthias Guillo, Chantal Fayad, Nabil Kaci, Melissa Neal, Emily A. Pettitt, Melissandre Pache, Qing Ye, My Chouinard, Eric L. Allen, Geneviève Baujat, Robert L. Hudkins, Michael B. Bober, Todd Harris, Ronald V. Swanson, and Laurence Legeai-Mallet. Tyra-300, an fgfr3-selective inhibitor, promotes bone growth in two fgfr3-driven models of chondrodysplasia. JCI Insight, Apr 2025. URL: https://doi.org/10.1172/jci.insight.189307, doi:10.1172/jci.insight.189307. This article has 2 citations and is from a domain leading peer-reviewed journal.